A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
A phase 2 trial of Sonrotoclax and Zanubrutinib in waldenström macroglobulinaemia, run by BeOne Medicines, active and no longer recruiting.
Overview
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia is a phase 2 interventional study registered as NCT05952037 by BeOne Medicines, with 114 participants enrolled, started 2023-10-23 and due to reach its primary completion in 2026-09-22. Interventions recorded: Sonrotoclax and Zanubrutinib.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialStudy of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Study of BGB-11417 in Participants With Myeloid Malignancies
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Shares Zanubrutinib and the tag pipeline.